Business Development

With global revenues of over US$ 4.5 billion, Mayaan  Pharma is the fifth largest specialty generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries worldwide. Mayaan Pharma  is also India’s largest and pharmaceutical company. Our global presence is supported by over 40 manufacturing facilities across six continents.

In the US market which contributes a significant share of our revenues, we are the leader in the generic dermatology segment. We have strong capabilities in developing generic and complex products with a robust pipeline of 118 ANDAs, including high value First-to-File (FTF) opportunities. We have an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia.

We are in constant search of partners who match our values, work ethics and commitment to patients. We regard partnership and collaboration as an integral part of our business strategy. This important initiative is supported by a dedicated team for global business development, licensing and post-alliance management.

Our track-record of successful collaborations includes in/out licensing of products and technologies, joint ventures, as well as acquisition of assets. We offer a full range of both global and local integrated, organisational and commercial capabilities, combined with a history of successful product launches.Ma

A) Generics and Differentiated Generics [505(b)2] In-licensing

We constantly seek to strengthen our presence, with a range of generic and specialty generic (505(b)2) products, in global markets.

Our primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.

All our efforts are towards continuing growth and to achieve this we are looking to in-license technology based specialty generics such as, but not limited to, long acting injectable, liposomes, implants, drug-device combination products, oral films, etc. for US market.

For Europe, our specialty business is focusing on hospital products which can be generic products or differentiated generic products including long acting injectable, liposomes etc. offering convenience to hospitals, patients and healthcare providers.

For Japan, the focus is on generic products for hospitals including Oncology. We are also looking for acquiring long listed brands in CNS, Derma, Anti-Infectives etc. We are also looking for opportunities for partnership on distribution of authorized generics for US and Japan.

We constantly seek to establish and strengthen long term, mutually rewarding business relationship based on suitable business models like co-development, licensing or fees for service. We believe in investing in our partners and extending all technical expertise wherever is required.